Remove Biopharma Remove Ethics Remove Food and Drug Administration
article thumbnail

Microscopic Markets with Macroscopic ImpactCrafting personalized campaigns for small patient populations.

PM360

This is partly due to the limited market potential for drugs in the space, but also due to the sheer volume of rare diseases: approximately 6,000–8,000 have been identified. This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline.

article thumbnail

Clinical trials and pregnancy: regulators weigh in

Clarivate

Drug developers often face a Catch-22 regarding clinical trials and pregnancy. How feasible is it to establish a drug’s safety for use in a population that may be unwilling or unable to participate in clinical trials? We look at the outcome of a recent Food and Drug Administration meeting and their draft guidance for more information.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How clinical outcome assessments can help us understand the patient experience

Clarivate

Clinical outcome assessments can take years to generate but may pay big dividends in patient-focused drug development, centering the patient experience and potentially bolstering a product’s case with regulators and payers. We developed or explored over 100 COAs and achieved ethical approval in multiple countries including the U.S.,

article thumbnail

Beyond animal testing: the rise of organs-on-chips technology

Clarivate

Food and Administration (FDA) approval, a change long sought by animal welfare organizations. Drugs can be now cleared for human trials using non-animal technologies developed over the last 10-15 years. Then, of course, there are the ethical considerations. Food and Drug Administration, 2023).